Marbox

1 x 100 ml

Liquid for injection, solution

Active substance

Marbofloxacin : 100 mg/ml

ATC code

QJ01MA93 Marbofloxacin

QJ01MA Fluoroquinolones

QJ01M Quinolone and quinoxaline antibacterials

QJ01 Antibacterials for systemic use

QJ Antiinfectives for systemic use

Species

Cattle and pigs (sows).

Indications

Cattle:

Therapeutic treatment of respiratory infections caused by sensitive strains of Pasteurella multocida, Mannheimia haemolytica and Histophilus somni. Therapeutic treatment of acute mastitis caused by E. coli strains sensitive to marbofloxacin during the lactation period.

Sows:

Treatment of Metritis Mastitis Agalactia Syndrome caused by bacterial strains sensitive to marbofloxacin.

Dose to be administered and administration route

Cattle :

Intramuscular use:

- Respiratory infections:

The recommended dosage is 8 mg/kg bodyweight i.e. 2 ml/25 kg bodyweight in a single injection.

If the volume to be injected is more than 20 ml, it should be divided between two or more injection sites.

Subcutaneous use:

- Acute mastitis:

The recommended dosage is 2 mg/kg i.e. 1 ml/50 kg bodyweight in a single daily injection, for 3 days.

The first injection may also be given by the intravenous route too.

Sows:

Intramuscular use:

The recommended dosage is 2 mg/kg i.e.1 ml/50kg bodyweight in a single daily injection by intramuscular route, for 3 days.

To ensure a correct dosage body weight should be determined as accurately as possible.

Adverse reactions

Cattle:

Undetermined frequency

Injection site pain^1,2

Injection site inflammation¹

Injection site fibrosis¹

Injection site oedema²

¹The process of cicatrisation starts rapidly (varying from fibrosis to synthesis of extracellular matrice and collagen) and may persist for at least 15 days after injection.

² After subcutaneous injection

Pigs (sows):

Undetermined frequency

Injection site inflammation¹ Injection site oedema¹

² persisting for 12 days after injection

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.